SHR-A1912

Antibody–drug conjugate

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Phase 3underway

Evidence outlook · registrational

Diffuse Large B-Cell Lymphoma: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2027-03.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Diffuse Large B-Cell Lymphoma
NCT06929624 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-04-24 – 2028-01 · Diffuse Large B-cell Lymphoma
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT06104553 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2023-11-17 – 2026-06 · B-cell Non-Hodgkin's Lymphoma
What this study did
Phase 1 (1)
Other / comorbidity
NCT05113069 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2021-12-22 – 2025-03-30 · B Cell Lymphoma
What this study did

Competitive landscape

This drug's own stage for Diffuse Large B-Cell Lymphoma: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
SHR-A1912: this drugPhase 3Antibody–drug conjugateCD79bnot yet gradedNo reviewed efficacy summary in this indication
Brentuximab VedotinApprovedAntibody–drug conjugateAnti-CD30 antibody-drug conjugatenot yet gradedNo reviewed efficacy summary in this indication
EpcoritamabApprovedMultispecific antibodyCD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
PF-05280586ApprovedBiologic (subtype unspecified)CD20not yet gradedNo reviewed efficacy summary in this indication
Rituximab (Rituxan)ApprovedMonoclonal antibodyCD20, CD20-directed Cytolytic Antibodynot yet gradedNo reviewed efficacy summary in this indication
TafasitamabApprovedMonoclonal antibodyCD19Weak signal
NCT02399085: Number of Participants With Best Objective Response Rate (ORR) (Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled): Treatment (MOR00208, Lenalidomide) — Approximately 4.5 years after first participant enrolled: 46 Participants; Approximately 6.5 years after first participant enrolled: 46 Participants
AcalabrutinibPhase 3Small moleculeBTKnot yet gradedNo reviewed efficacy summary in this indication
ChidamidePhase 3Small moleculeHDACnot yet gradedNo reviewed efficacy summary in this indication
IbrutinibPhase 3Small moleculeBTKnot yet gradedNo reviewed efficacy summary in this indication
OdronextamabPhase 3Multispecific antibodyCD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
Purinostat MesylatePhase 3Small moleculeHDACnot yet gradedNo reviewed efficacy summary in this indication
Zilovertamab VedotinPhase 2/3Antibody–drug conjugateROR1not yet gradedNo reviewed efficacy summary in this indication
Zugocabtagene Geleucel
Phase 1/2(overall)
Cell therapyCD19not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow SHR-A1912 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
March 2027 (1)
Phase 3Diffuse Large B-Cell LymphomaActive not recruiting
Est. primary completion 2027-03 · NCT06929624 · CT.gov ↗
What to watch

See the full readout calendar ↗